RESEARCH MINUTE

Diabetes Drug rosiglitazone (Avandia®) Associated with Heart Failure and Death

People taking pioglitazone (Actos®) had a 23% lower risk of heart failure and a 14% lower risk of death than people taking rosiglitazone (Avandia®).

What does this mean?

- Rosiglitazone (Avandia®) and pioglitazone (Actos®) are oral drugs used to treat people with Type II diabetes.
- If 100 people took rosiglitazone (Avandia®) instead of pioglitazone (Actos®) for a year, our research suggests that one additional person would experience heart failure, a heart attack, or would die.

Policy Implications

Funding guidelines for the prescribing of thiazolidinediones for patients with Type II diabetes should be changed to reflect the evidence that pioglitazone (Actos®) is recommended over rosiglitazone (Avandia®), and specifically that rosiglitazone (Avandia®) should not be prescribed.

How do we know this?

These findings are the results of a population-based study in which the ODPRN tracked the health records of Ontario residents over the age of 65 who had Type II diabetes, had been prescribed rosiglitazone (Avandia®), or pioglitazone (Actos®) for the first time between 2002 and 2008, and were not taking insulin at the same time. Patients taking rosiglitazone (Avandia®) (22,785) were matched to similar patients taking pioglitazone (Actos®) (16,951). People taking pioglitazone (Actos®) had a 23% lower risk of heart failure (hazard ratio of .77) and a 14% lower risk of death (hazard ratio of .86) than people taking rosiglitazone (Avandia®) within a year of their first heart attack.


This Research Minute was created by the ODPRN.
The ODPRN is funded by the Ontario Drug Innovation Fund to respond rapidly and directly to policy-makers’ needs for relevant research. For more information about the ODPRN please visit our website www.odprn.ca.